Trang 1 từ 51 các kết quả
CROSS REFERENCE TO A RELATED APPLICATION
This application is a National Stage Application of International Application Number PCT/EP2009/005465, filed Jul. 28, 2009; which claims priority to European Application No. 08013561.9, filed Jul. 28, 2008; which are incorporated herein by reference in their
The invention relates to a protease for activating the blood clotting factor VII, to a process for isolating it, detecting it and inactivating it, and to medicinal preparations which comprise this protease.
BACKGROUND OF THE INVENTION
The blood clotting system comprises two different, cascade-like
BACKGROUND OF THE INVENTION
The invention relates to inhibitors of trypsin-like serine proteases of the general formula
##STR00001## which, besides plasmin, also inhibit plasma kallikrein, and to the preparation and use thereof as medicaments, preferably for the treatment of blood loss, especially
BACKGROUND OF THE INVENTION
The invention relates to inhibitors of trypsin-like serine proteases of the general formula
##STR00001## which, besides plasmin, also inhibit plasma kallikrein, and to the preparation and use thereof as medicaments, preferably for the treatment of blood loss, especially
BACKGROUND OF THE INVENTION
The invention relates to inhibitors of trypsin-like serine proteases of the general formula
##STR00001## which, besides plasmin, also inhibit plasma kallikrein, and to the preparation and use thereof as medicaments, preferably for the treatment of blood loss, especially
FIELD OF THE INVENTION
The invention is concerned with the use of the protease domain of human plasminogen activator, medicaments for the treatment of thromboembolic diseases, pharmaceutical compositions which contain, as an active component, said protein, and the uses thereof.
BACKGROUND AND PRIOR
FIELD OF THE INVENTION
The invention is concerned with the use of the protease domain of human plasminogen activator, medicaments for the treatment of thromboembolic diseases, pharmaceutical compositions which contain, as an active component, said protein, and the uses thereof.
BACKGROUND AND PRIOR
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
A protease for activating the blood clotting factor VII is described, which a) is inhibited by the presence of aprotinin, b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more
FIELD OF THE INVENTION
This application relates generally to the field of viral disease, prophylaxis, and vaccination. More specifically, it provides a virus vaccine modeled on the etiologic agent for Crimean-Congo hemorrhagic fever. It was produced by reducing the deubiquinating and deISGylating
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE
The Sequence Listing written in file U.S. Pat. No. 934,365_ST25.TXT, created on Jul. 7, 2014, 108,900 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated
SEQUENCE LISTING
The instant application contains a Sequence Listing (.txt file named Sequence_Listing, having a date of May 4, 2018 and 63,944 bytes in size) which has been submitted in ASCII format via EFS-Web and is incorporated by reference herein.
FIELD
This invention relates to modified serpin